Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pepinemab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Vaccinex
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pepinemab + trastuzumab is an investigational combination therapy consisting of two monoclonal antibodies. Pepinemab is a humanized IgG4 monoclonal antibody that targets semaphorin 4D (SEMA4D), modulating the tumor microenvironment to enhance anti-tumor immune responses. Trastuzumab is a well-established monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), inhibiting HER2-mediated signaling and promoting immune-mediated cytotoxicity against HER2-positive cancer cells. The combination aims to leverage both direct anti-tumor effects and modulation of the immune response in patients with HER2-positive metastatic breast cancer. This regimen has been studied in conjunction with dendritic cell vaccines and adoptive T-cell therapy to further augment immunogenicity[1][3][5].
- Other names
- pepinemab + trastuzumab
02
Targets
SEMA4D (Semaphorin 4D)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pepinemab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pepinemab + trastuzumab.